Member Info for Laura2022

In the presentation they talked of longer and more substantial opportunities for contracts from the new division

The average contract size has almost trebled over the last 12mths so it's not beyond realms of possibly that PYC could soon be winning £200k-400k + long term contracts going forward

This was from results to June 2024

Implementation of the Company’s Personalised Dosing Software onto DoseMe’s newly launched platform, allowing access to the software for research purposes initially, with the aim to add paid for functionality later• Awarded two large contracts exceeding £286k, in aggregate, with two new clients, one of whom is at the forefront of AI driven drug discovery• Follow-on contracts with Bicycle Therapeutics, Numab Therapeutics, Merck KGaA and Sheffield University exceeding, in aggregate, £822k• Continued operational build of a Biosta

1.44p

Thanks Debull

This is what PYC said as part of their summary yesterday

"our exciting step towards a personalised oncology dosing tool for chemotherapy-induced neutropenia".

Rns reach

So we're all clear

What is your exact current position ?

I ask as it changes all the time

So Uncanny

Are you now completely sold out or do you hold?

Or can you not remember

Physiomics plc

1,689 followers

2h Edited

What a fantastic few days at #ENASymp24 so far! 🎉 Today's highlight was our poster presentation, where we shared insights from the PARTNER study – our exciting step towards a personalised oncology dosing tool for chemotherapy-induced neutropenia. A huge thank you to everyone who stopped by and chatted with Physiomics plc's Léa Sta, PhD!

As we wrap up tomorrow, we’re excited to keep the conversations going about how Model-Informed Drug Development (MIDD) can lead to smarter decision-making in drug development.

Https://www.bbc.co.uk/news/health-62755001

From VAL

Large market opportunity. The prostate cancer market is worth many billions of pounds.

Multi cancer potential. What was it 30 million extra on top of the 61 million for each additional indication.

Strong demand for better prostate treatments.

Milestones.

Intellectual property strength across the US and Europe with potential to reformulate the drug.

Ultimately it would be down to the science but the previous trials were promising. We know VAL201 is very safe and tolerable therefore that derisks any investment with a potential for very high returns. Nothing is guaranteed in drug development.

Previous trial results indicated that the tumour had stopped growing in cases so results were positive with significant potential. The trials were done at lower dosages but that should increase the efficiency past the 50% from the previous trial.

I have attended the 2 recent presentations from 2 companies on my wagon whelk

Expecting material developments on the P one

Large volume again

It's like a new Newuncle..great to see and great info

We will know more after the 25th Oct and is really not worth pondering on given thr other things in the pipeline as discussed at the presentation 2 weeks ago

Grainger

Get a hobby

New Haven, Conn., October 23, 2024 – Modifi Biosciences, Inc. (“Modifi

Biosciences”) a leader in the development of direct DNA modification

enabled cancer therapeutics, today announced that the company has been

acquired by Merck, known as MSD outside of the United States and Canada.

“In founding Modifi Biosciences, we sought to radically change the oncology

treatment paradigm for cancer patients with glioblastoma and other

tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founder,

Harvey and Kate Cushing, Professor of Therapeutic Radiology at Yale School

of Medicine, and Scientific Director of the Yale Brain Tumor Center at Smilow

Cancer Hospital. “We are honored to have Merck recognize the potential of

our science, and as an oncology company, they are perfectly positioned to

advance our innovations through clinical trials and commercialization.”

Under the terms of the agreement Merck, through a subsidiary, has acquired

all outstanding shares of Modifi Biosciences for $30 million upfront. Modifi

He might as well monitor the price of methane as that's all Mr Bell delivers

Yes

Ceo says is he in constant talks with THX and their bankers/funders

Very intriguing

You haven't still answered why you had a 9 year gap in posting

I suspect all is not as it seems

I see your choose SCE as a wise investment which has admitted its got no money and is burning £9mln a year with no revenues to speak of

And still no changes down on the major holders

Facts , as Mozak says are PYC are £1.4mln yet

Record revenues won 2023/24

Record revenues booked 2024 already for H2

Cash of £600k or so after recent fund raise

Potential for up to £6mln from VAL201 sub license ( see Feb 2021)

Personalised medicine software platforms are worth $blns in savings and PYC are at final stages of their software dosing app being at revenue generation stage largely with USA partner DoseMeRx

Directors have lowest wages on AIM..eg CEO at £70k is a fraction of other unscrupulous CeoS on AIM

A very good recent webinar ( see Trench123 notes)

Very modest Ceo salary and he's had vast experience in life sciences markets and already cut out the dead wood director (may 2024) and 6mths i into a fresh focus of the business and business divi9sons

Personalised dosing app nearing commercialisation (see King Homer posts)

Comapres to BLU etc this is, in my view, a genuine investment with huge growth potential and a BOD who are alligned via very modest salaries for the revenues they deliver (please see my posts over the weekend and today )

Best wishes

L x